DCPAR for Rizatriptan 5 mg and 10 mg Tablets ...
PAR Rizatriptan 5 mg and 10 mg Tablets/Orodispersible Tablets UK/H/3396-7/001-2/DC 2 LAY SUMMARY On 12th December 2012, the Medicines and Healthcare products Regulatory Agency (MHRA) granted Marketing Authorisations (licences) to Arrow Generics Limited for the
Download DCPAR for Rizatriptan 5 mg and 10 mg Tablets ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
The Human Medicines Regulations 2012 – …
www.mhra.gov.ukThe Human Medicines Regulations 2012 – description of each Part This document provides a brief overview of each Part of the Human Medicines Regulations 2012 …
FULTIUM -D 800 IU CAPSULES - GOV.UK
www.mhra.gov.ukVitamin D deficiency, with levels of 25(OH)D below 25nmol/L (10ng/ml), could result in the disease rickets (or osteomalacia). The disease resulting as a deficiency is considered to be due to malabsorption
GLYCOPYRRONIUM BROMIDE 0.2MG/ML …
www.mhra.gov.ukUKPAR Glycopyrronium Bromide 0.2 mg/ml Solution for Injection PL 00156/0115 1 GLYCOPYRRONIUM BROMIDE 0.2MG/ML SOLUTION FOR INJECTION (PL 00156/0115)
Meloxicam - GOV.UK
www.mhra.gov.ukPL 31388/0003-4 UKPAR Alpex Pharma (UK) Ltd, Meloxicam 7.5mg and 15mg Orodispersible Tablets 3 Scientific Discussion INTRODUCTION Based on the review of the data on quality, safety and efficacy, the UK granted
PL 00010/0643 - GOV.UK
www.mhra.gov.ukUKPAR Canesten HC Cream PL 00010/0643 6 All excipients comply with their respective European Pharmacopoeia monographs, except triceteareth-4-
Public Assessment Report UKPAR Canesten Combi …
www.mhra.gov.ukThis is a summary of the Public Assessment Report (PAR) for Canesten Combi Pessary & External Cream 500mg / 2% w/w pessary & cream (PL 00010/0653).
DCPAR for Ampicillin-Salbactam 1 g--0 5 and 2 g-1 g ...
www.mhra.gov.ukPAR Ampicillin/Sulbactam 1 g/0.5 g and 2 g/1 g powder for Solution for Injection or Infusion UK/H/4322/001-2/DC 1 Public Assessment Report Decentralised Procedure
Public Assessment Report Mutual Recognition …
www.mhra.gov.ukPAR Sayana 104mg/0.65ml Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104MG/0.65ML SUSPENSION FOR INJECTION
Cefixime 400 mg Film-coated Tablets, PL 22805 …
www.mhra.gov.ukMHRA PAR; CEFIXIME 400 MG FILM-COATED TABLETS, PL 22805/0032-3 2 Lay summary The Medicines and Healthcare products Regulatory Agency …
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure LIOTHYRONINE SODIUM 20 MICROGRAM TABLETS (liothyronine sodium) Procedure No: UK/H/6516/001/DC
Related documents
PRODUCTS PRESENTATION REFERENCE - substipharm.fr
substipharm.frProduct availability is subject to patent restrictions in countries where applicable patents are in force. 02/2018 PRODUCTS PRESENTATION REFERENCE
New Zealand Datasheet 1 PRODUCT NAME Ondansetron …
www.medsafe.govt.nzNew Zealand Datasheet 1 PRODUCT NAME Ondansetron-DRLA tablets Ondansetron ODT-DRLA tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ondansetron hydrochloride dihydrate tablets 4 mg and 8 mg
Olanzapine 5,10,15mg Orodispersible Tablets - GOV.UK
www.mhra.gov.ukUKPAR Olanzapine 5mg, 10mg and 15mg Orodispersible Tablets PL 33410/0024-6 & 0084-6 6 DRUG PRODUCT Other ingredients Other ingredients in the tablet core consist of pharmaceutical excipients lactose monohydrate,
NEW - de-group.co.uk
de-group.co.uk3 Prices subject to change. Stock subject to availability. oth West Office 0800 279 2593 oth East Office 0800 542 3072 Eclise enerics 0800 328 7169 Crosspharma
Workshop Summary: AAPS Workshop on Special Dosage …
www.dissolutiontech.comDissolution Technologies | NOVEMBER 2010 47 e-mail: vagray@rcn.com Workshop Summary: AAPS Workshop on Special Dosage Forms—What’s New with In Vitro Drug Release? Vivian Gray
6 Choice of medication formulation - Pharmaceutical Press
www.pharmpress.com6 Choice of medication formulation Rebecca White Key Points l Solutions or soluble tablets are the formulations of choice. l Do not assume that liquid formulation will be suitable. l Do not crush tablets or open capsules unless an alternative formulation or drug is unavailable. When deciding which medication formulation is appropriate for administration via an
Optimization and Formulation of Orodispersible Tablets of ...
www.tjpr.orgSingh & Singh Trop J Pharm Res, April 2009; 8 (2): 157 Table 3: Physical properties of orodispersible tablets of meloxicam Parameter* Formulation F 1 F 2 F 3 …